Gene-directed therapy in glaucoma may have future clinical applications

The approach to lowering intraocular pressure reduces medication burden without risking graft rejection

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

The company announced new data on outcomes for both open and narrow angle glaucoma patients.

According to the company, the deal expands its European footprint into Spain and Portugal.

Hundreds of previously-unknown genes could be vital for early detection and treatment.

The open-access tool is the official registry partner of the European Glaucoma Society.